Gilead Gains European Approval to Market Combination Antiretroviral Drug Truvada
February 25, 2005
Foster City, Calif.-based biotech company Gilead on Wednesday received approval from the European Commission to market its combination antiretroviral drug Truvada in all 25 European Union countries, the AP/Forbes reports. Truvada is a once-daily combination pill containing the antiretroviral drugs Emtriva and Viread, known generically as emtricitabine and tenofovir, respectively. The drugs work by blocking HIV's reverse transcriptase enzyme to prevent viral replication (AP/Forbes, 2/23). The drug was approved for marketing in the United States in August 2004, according to San Francisco Business Times (San Francisco Business Times, 2/23).
Combination Therapy Might Be Better Choice Than Nevirapine Alone to Prevent Vertical HIV Transmission, Researchers Say
UNFPA Calls for Increased HIV/AIDS Prevention, Family Planning in Light of World Population Projection for 2050
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.